Cyclic pyrazinoylguanidine sodium channel blockers

Details Cyclic pyrazinoylguanidine sodium channel blockers Cyclic pyrazinoylguanidine sodium channel blockers

2004-08-18

2008-01-08

Tucker, Zachary C. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S252110, C544S357000, C544S407000

Reexamination Certificate

active

07317013

ABSTRACT:
The present invention provides sodium channel blockers represented by formula (I):where the structural variables are defined herein. The compounds of the present invention may be used for treating a variety of conditions as described herein.

REFERENCES:
patent: 6858614 (2005-02-01), Johnson
patent: 6858615 (2005-02-01), Johnson
patent: 6903105 (2005-06-01), Johnson
patent: 2004/0198744 (2004-10-01), Johnson
patent: 2004/0198745 (2004-10-01), Johnson
patent: 2004/0198746 (2004-10-01), Johnson
patent: 2004/0198747 (2004-10-01), Johnson
patent: 2004/0198748 (2004-10-01), Johnson
patent: 2004/0198749 (2004-10-01), Johnson
patent: 2004/0204424 (2004-10-01), Johnson
patent: 2004/0204425 (2004-10-01), Johnson
patent: 2004/0229884 (2004-11-01), Johnson
patent: 2005/0080091 (2005-04-01), Johnson et al.
patent: 2005/0080093 (2005-04-01), Johnson et al.
patent: 2005/0090505 (2005-04-01), Johnson et al.
patent: 2005/0113388 (2005-05-01), Johnson
patent: 2005/0113389 (2005-05-01), Johnson
patent: 2005/0113390 (2005-05-01), Johnson
John B. Bicking, et al., “Pyrazine Diuretics. I. N-Amidino-3-amino-6-halopyrazinecarboxamides”, J. Med. Chem, vol. 8, No. 5, 1965, pp. 638-642.

Affiliated with

Also associated with

Rating

Cyclic pyrazinoylguanidine sodium channel blockers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic pyrazinoylguanidine sodium channel blockers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic pyrazinoylguanidine sodium channel blockers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3965152